Logo image of PETS

PETMED EXPRESS INC (PETS) Stock Fundamental Analysis

NASDAQ:PETS - Nasdaq - US7163821066 - Common Stock - Currency: USD

3.55  -0.22 (-5.84%)

After market: 3.86 +0.31 (+8.73%)

Fundamental Rating

4

Overall PETS gets a fundamental rating of 4 out of 10. We evaluated PETS against 122 industry peers in the Specialty Retail industry. PETS has a great financial health rating, but its profitability evaluates not so good. PETS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year PETS was profitable.
PETS had a positive operating cash flow in the past year.
Of the past 5 years PETS 4 years were profitable.
In the past 5 years PETS always reported a positive cash flow from operatings.
PETS Yearly Net Income VS EBIT VS OCF VS FCFPETS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

The Return On Assets of PETS (0.25%) is comparable to the rest of the industry.
PETS has a Return On Equity of 0.37%. This is comparable to the rest of the industry: PETS outperforms 55.74% of its industry peers.
PETS has a Return On Invested Capital (1.24%) which is in line with its industry peers.
Industry RankSector Rank
ROA 0.25%
ROE 0.37%
ROIC 1.24%
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
PETS Yearly ROA, ROE, ROICPETS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

PETS has a Profit Margin (0.14%) which is comparable to the rest of the industry.
With a Operating Margin value of 0.62%, PETS is not doing good in the industry: 61.48% of the companies in the same industry are doing better.
Looking at the Gross Margin, with a value of 27.68%, PETS is doing worse than 70.49% of the companies in the same industry.
In the last couple of years the Gross Margin of PETS has declined.
Industry RankSector Rank
OM 0.62%
PM (TTM) 0.14%
GM 27.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
PETS Yearly Profit, Operating, Gross MarginsPETS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PETS is destroying value.
PETS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PETS has more shares outstanding
PETS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PETS Yearly Shares OutstandingPETS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
PETS Yearly Total Debt VS Total AssetsPETS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

PETS has an Altman-Z score of 3.63. This indicates that PETS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 3.63, PETS belongs to the best of the industry, outperforming 80.33% of the companies in the same industry.
PETS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.63
ROIC/WACC0.13
WACC9.55%
PETS Yearly LT Debt VS Equity VS FCFPETS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.43 indicates that PETS should not have too much problems paying its short term obligations.
PETS's Current ratio of 1.43 is in line compared to the rest of the industry. PETS outperforms 56.56% of its industry peers.
A Quick Ratio of 1.18 indicates that PETS should not have too much problems paying its short term obligations.
PETS has a better Quick ratio (1.18) than 80.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 1.18
PETS Yearly Current Assets VS Current LiabilitesPETS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2

3. Growth

3.1 Past

PETS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.56%, which is quite impressive.
Looking at the last year, PETS shows a very negative growth in Revenue. The Revenue has decreased by -10.82% in the last year.
The Revenue has been decreasing by -0.17% on average over the past years.
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
Revenue 1Y (TTM)-10.82%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.88%

3.2 Future

Based on estimates for the next years, PETS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.76% on average per year.
PETS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -6.06% yearly.
EPS Next Y79.08%
EPS Next 2Y33.33%
EPS Next 3Y23.76%
EPS Next 5YN/A
Revenue Next Year-17.67%
Revenue Next 2Y-10.36%
Revenue Next 3Y-6.06%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PETS Yearly Revenue VS EstimatesPETS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
PETS Yearly EPS VS EstimatesPETS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5 2

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 355.00, which means the current valuation is very expensive for PETS.
PETS's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.93, PETS is valued quite expensively.
PETS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 355
Fwd PE N/A
PETS Price Earnings VS Forward Price EarningsPETS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PETS indicates a rather cheap valuation: PETS is cheaper than 94.26% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PETS is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 85.78
EV/EBITDA 3.31
PETS Per share dataPETS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PETS does not grow enough to justify the current Price/Earnings ratio.
PETS's earnings are expected to grow with 23.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.49
PEG (5Y)N/A
EPS Next 2Y33.33%
EPS Next 3Y23.76%

0

5. Dividend

5.1 Amount

PETS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PETMED EXPRESS INC

NASDAQ:PETS (7/28/2025, 8:00:00 PM)

After market: 3.86 +0.31 (+8.73%)

3.55

-0.22 (-5.84%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)07-28 2025-07-28
Inst Owners41.43%
Inst Owner Change-0.28%
Ins Owners7.33%
Ins Owner Change4.97%
Market Cap73.34M
Analysts42.86
Price Target3.42 (-3.66%)
Short Float %9.24%
Short Ratio10.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.59
Dividend Growth(5Y)-11.13%
DP54.34%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-96.08%
Min EPS beat(2)-488.23%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)-36.55%
Min EPS beat(4)-488.23%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)-169.93%
EPS beat(12)4
Avg EPS beat(12)-128.55%
EPS beat(16)4
Avg EPS beat(16)-101.84%
Revenue beat(2)0
Avg Revenue beat(2)-12.18%
Min Revenue beat(2)-12.84%
Max Revenue beat(2)-11.51%
Revenue beat(4)1
Avg Revenue beat(4)-8.81%
Min Revenue beat(4)-12.84%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-6.94%
Revenue beat(12)1
Avg Revenue beat(12)-6.81%
Revenue beat(16)1
Avg Revenue beat(16)-6.96%
PT rev (1m)-6.94%
PT rev (3m)-6.94%
EPS NQ rev (1m)-655.56%
EPS NQ rev (3m)-655.56%
EPS NY rev (1m)-139.02%
EPS NY rev (3m)-139.02%
Revenue NQ rev (1m)-5.37%
Revenue NQ rev (3m)-5.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.63%
Valuation
Industry RankSector Rank
PE 355
Fwd PE N/A
P/S 0.3
P/FCF 85.78
P/OCF 15.18
P/B 0.76
P/tB 1.35
EV/EBITDA 3.31
EPS(TTM)0.01
EY0.28%
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.04
FCFY1.17%
OCF(TTM)0.23
OCFY6.59%
SpS11.96
BVpS4.66
TBVpS2.64
PEG (NY)4.49
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.25%
ROE 0.37%
ROCE 1.57%
ROIC 1.24%
ROICexc 2.57%
ROICexgc 23.86%
OM 0.62%
PM (TTM) 0.14%
GM 27.68%
FCFM 0.35%
ROA(3y)2.57%
ROA(5y)8.14%
ROE(3y)2.43%
ROE(5y)9.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-3.61%
F-Score7
Asset Turnover1.71
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 57.96%
Cap/Sales 1.61%
Interest Coverage 250
Cash Conversion 57.63%
Profit Quality 239.5%
Current Ratio 1.43
Quick Ratio 1.18
Altman-Z 3.63
F-Score7
WACC9.55%
ROIC/WACC0.13
Cap/Depr(3y)91.99%
Cap/Depr(5y)95.64%
Cap/Sales(3y)1.43%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70%
EPS Next Y79.08%
EPS Next 2Y33.33%
EPS Next 3Y23.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.82%
Revenue growth 3Y-3.13%
Revenue growth 5Y-0.17%
Sales Q2Q%-18.88%
Revenue Next Year-17.67%
Revenue Next 2Y-10.36%
Revenue Next 3Y-6.06%
Revenue Next 5YN/A
EBIT growth 1Y111.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.4%
EBIT Next 3Y51.6%
EBIT Next 5YN/A
FCF growth 1Y-96.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.97%
OCF growth 3Y-52.42%
OCF growth 5Y-37.46%